<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867421</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003-TANOs</org_study_id>
    <nct_id>NCT04867421</nct_id>
  </id_info>
  <brief_title>Neutrophils in Bone Sarcomas</brief_title>
  <acronym>TANOs</acronym>
  <official_title>Assessment of the Presence, and Characterization, of Tumor-associated Neutrophils in Bone Sarcomas: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Reims Champagne-Ardenne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Reims Champagne-Ardenne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Tumor infiltrating neutrophils are present in osteosarcomas and chondrosarcomas&#xD;
      and&#xD;
&#xD;
      Experimental design: Exploratory observational research&#xD;
&#xD;
      Population: Adult patients with osteosarcoma or chondrosarcoma&#xD;
&#xD;
      Assessment criteria: Determination of the presence of TANs within tumors and their N1 or N2&#xD;
      profile, the presence of other immune cells, and the PDL-1 status of the tumor.&#xD;
&#xD;
      Investigation plan: Proposal to participate at all eligible patient during the preoperative&#xD;
      consultation. If the patient agrees to participate in the study he/she will be included.&#xD;
      Participation in the study will not affect its coverage. Patient participation will lead to:&#xD;
&#xD;
        -  Taking samples from an operative part,&#xD;
&#xD;
        -  The collection of demographic data (age, sex, height, weight, body mass index), family&#xD;
           history of cancer, history of bone trauma, sports practice, clinical and&#xD;
           anatomopathology reports and data, medical history (Diabetes, Cardiovascular Diseases,&#xD;
           Infectious Diseases, Autoimmune Diseases, Bone Metabolism Disorders, Allergies,&#xD;
           Menopause, Drug treatments followed, Psychiatric disorders).&#xD;
&#xD;
      Statistical analysis plan: Description in frequency of the presence of TANs, of N1 and N2&#xD;
      profiles, of the presence of other immune cells both qualitatively and quantitatively.&#xD;
      Analysis in subgroups on relevant criteria (age, sex, location, type of tumor).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the presence of neutrophils in sarcoma-affected tissues</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Flow cytometry analysis on excised tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of flow cytometry and histology for neutrophil assessment in sarcoma-affected tissues</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Neutrophil identification thanks to CD66b marker with both the techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of neutrophils N1 or N2 profile in sarcoma-affected tissues</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Flow cytometry (CD45 CD66b CD182 CD184 CD195)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of non-neutrophil leukocytes in sarcoma-affected tissues</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Flow cytometry analysis (CD45 CD3 CD4 CD8 CD19 CD33 CD80 CD163)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of PDL1 status of neutrophils in sarcoma-affected tissues</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Flow cytometry analysis (CD45 CD66b CD 274)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Osteosarcoma, Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>TANOs</arm_group_label>
    <description>Adult patients with osteosarcoma or chondrosarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>TANOs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with osteosarcoma or chondrosarcoma consulting the Orthopedic and&#xD;
        Traumatological Surgery Department of the Reims University Hospital or the Godinot&#xD;
        Institute and undergoing tumor resection surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient of 18 years and more&#xD;
&#xD;
          -  Patient of the Orthopedic and Traumatological Surgery Department of the Reims&#xD;
             University Hospital or the Godinot Institute&#xD;
&#xD;
          -  Patient with osteosarcoma or chondrosarcoma to be operated on regardless of stage.&#xD;
&#xD;
          -  Patient agreeing to participate in the study (informed consent form)&#xD;
&#xD;
          -  Patient fluent in French&#xD;
&#xD;
          -  Patient affiliated with a social security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having a medical history that may compromise the protocol (psychiatric,&#xD;
             medical or pharmacological disorders such as the use of anti-inflammatory drugs, or&#xD;
             any compound that may alter or modify the inflammatory reaction in the week preceding&#xD;
             the protocol).&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patient with eating disorders (anorexia, bulimia, overeating)&#xD;
&#xD;
          -  Patient protected by law (guardianship, curatorship, hospitalized without their&#xD;
             consent and not protected by law, deprived of liberty)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe MESA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Reims Champagne-Ardenne - CHU de Reims</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe MESA</last_name>
    <phone>03 26 78 77 51</phone>
    <email>cmensa@chu-reims.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric VELARD</last_name>
    <phone>03 26 91 80 10</phone>
    <email>frederic.velard@univ-reims.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université de Reims Champagne-Ardenne</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric VELARD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteosarcoma</keyword>
  <keyword>Chondrosarcoma</keyword>
  <keyword>Tumor associated neutrophils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

